Long-term survivors of gastric cancer: A California population-based study

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3507-3515

  Kunz, Pamela L ^a   Gubens, Matthew ^a   Fisher, George A ^a   Ford, James M ^a   Lichtensztajn, Daphne Y ^b   Clarke, Christina A ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIA; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; ESOPHAGUS; FEMALE; GASTRECTOMY; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HISPANIC; HISTOPATHOLOGY; HOSPITAL BED CAPACITY; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PACIFIC ISLANDER; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS; STOMACH ADENOCARCINOMA; STOMACH ANTRUM; STOMACH FUNDUS; SURVIVAL RATE; TREATMENT RESPONSE; UNITED STATES;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CALIFORNIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OCEANIC ANCESTRY GROUP; STOMACH NEOPLASMS; SURVIVORS;

EID: 84867066324     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.8028     Document Type: Article

References (27)

1. Jemal A, Center MM, DeSantis C, et al: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907, 2010
2. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011
3. Parfitt JR, Miladinovic Z, Driman DK: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada: An epidemiological study from 1964-2002. Can J Gastroenterol 20:271-276, 2006
4. Henson DE, Dittus C, Younes M, et al: Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: Increase in the signet ring cell type. Arch Pathol Lab Med 128:765-770, 2004 (Pubitemid 38856886)
5. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100:1184-1187, 2008
6. Lagergren J, Bergström R, Lindgren A, et al: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825-831, 1999 (Pubitemid 29142625)
7. Lagergren J, Bergström R, Nyrén O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130:883-890, 1999 (Pubitemid 29239582)
8. Altekruse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2007/
9. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
10. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
11. Wagner A, Grothe W, Behl S, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2:CD004064, 2005
12. Adachi Y, Mori M, Maehara Y, et al: Long-term survival after resection for advanced gastric carcinoma. J Clin Gastroenterol 21:208-210, 1995
13. Hochwald SN, Kim S, Klimstra DS, et al: Analysis of 154 actual five-year survivors of gastric cancer. J Gastrointest Surg 4:520-525, 2000
14. Kakeji Y, Maehara Y, Tomoda M, et al: Long-term survival of patients with stage IV gastric carcinoma. Cancer 82:2307-2311, 1998 (Pubitemid 28283435)
15. Kim DY, Joo JK, Park YK, et al: Predictors of long-term survival in node-positive gastric carcinoma patients with curative resection. Langenbecks Arch Surg 392:131-134, 2007 (Pubitemid 46328674)
16. Takahashi I, Matsusaka T, Onohara T, et al: Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 47:1485-1488, 2000
17. Tominaga K, Koyama Y, Sasagawa M, et al: A follow-up study of resected stomach cancer patients with special emphasis on the incidence of second primary cancers. Jpn J Clin Oncol 23:331-335, 1993
18. Yoshida M, Ohtsu A, Boku N, et al: Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 34:654-659, 2004 (Pubitemid 41615277)
19. Kim T, Ben-David K, Grobmyer SR, et al: Esophageal cancer: The five-year survivors. 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 22-24, 2010 (abstr 80)
20. Yost K, Perkins C, Cohen R, et al: Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703-711, 2001 (Pubitemid 32803497)
21. Clarke CA, Glaser SL, Keegan TH, et al: Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev 14:1441-1447, 2005 (Pubitemid 40807343)
22. Keegan TH, Glaser SL, Clarke CA, et al: Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study. J Clin Oncol 23:7604-7613, 2005 (Pubitemid 46291824)
23. Macdonald JS, Benedetti J, Smalley S, et al: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27:205s, 2009 (suppl; abstr 4515)
24. Kozak KR, Moody JS: The survival impact of the Intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 72:517-521, 2008
25. Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007 (Pubitemid 350044801)
26. Kang Y, Ohtsu A, Van Cutsem E, et al: AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. J Clin Oncol 28:302s, 2010 (suppl; abstr LBA4007)
27. Smyth EC, Enzinger PC, Li J, et al: Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. J Clin Oncol 29:269s, 2011 (suppl; abstr 4056)